Current First-Line Medical Treatment for Endometriosis-Related Pain
Start with oral contraceptives or progestin-only therapy as first-line treatment for endometriosis-related pain, reserving GnRH agonists and the newer oral GnRH antagonists for second-line use when first-line agents fail to control symptoms.
First-Line Treatment Options
The evidence strongly supports combined oral contraceptives (COCs) and progestins as equally effective first-line therapies for endometriosis-associated pain 1. These medications work by suppressing ovarian function and inducing atrophy of endometrial tissue, thereby reducing inflammation and pain symptoms.
Progestin-Only Options
Progestins are highly effective with reduced side effects compared to other hormonal therapies 2. The available formulations include:
Oral progestins (dienogest 2 mg, norethisterone acetate, medroxyprogesterone acetate): Oral progestins probably reduce overall pain (MD -2.58 on VAS scale) and dysmenorrhea compared to placebo 3. Dienogest has become one of the most widely used drugs for long-term treatment across all endometriosis phenotypes 2, 4.
Depot medroxyprogesterone acetate: Effective for pain relief and may be equivalent to more costly regimens 1. When compared to GnRH agonists, depot progestagens slightly reduce dysmenorrhea risk (RR 0.93) with probably lower cumulative side effects (RR 0.03) 3.
Levonorgestrel intrauterine system (LNG-IUS): Can be offered as first-line therapy and is associated with pain relief 4, 5. This provides a long-term treatment option with localized hormonal effects.
Subcutaneous etonogestrel implant: Valid alternative for long-term treatment 2.
Combined Oral Contraceptives
COCs are effective compared to placebo and may be equivalent to other more costly regimens for pain relief 1. Common side effects include breakthrough bleeding, nausea, headaches, breast tenderness, and libido changes 6.
When choosing between progestins and COCs: Recent evidence suggests dienogest 2 mg is at least as effective as CHC and can be used as an alternative for first-line treatment 4. The choice depends on contraceptive needs, side effect profile tolerance, and patient preference.
Second-Line Treatment Options
GnRH Agonists
Reserve GnRH agonists for patients whose symptoms fail to be controlled by first-line agents 7, 4. Treatment with a GnRH agonist for at least 3 months is equally effective as danazol for at least 6 months for pain relief 1.
Critical caveat: When using GnRH agonists for continued therapy, always add add-back therapy (norethisterone acetate or low-dose combined contraceptives) to reduce or eliminate bone mineral loss without reducing pain relief efficacy 1, 6. This is Level A evidence.
Side effects include vasomotor symptoms (hot flushes), urogenital atrophy, and bone mineral density loss, which limit long-term use 8, 6.
Oral GnRH Antagonists (Emerging Second-Line Option)
Oral GnRH antagonists (elagolix, relugolix, linzagolix) represent promising new treatments that will soon be available in France and other markets 4, 9. They offer several advantages over GnRH agonists:
- Rapid action with no flare-up effect (unlike agonists which initially stimulate before suppressing) 4, 8
- Oral administration for improved convenience 4
- Dose-adjustable hormonal suppression 8
- Comparable efficacy to GnRH agonists 4, 9
However, they share similar hypoestrogenic side effects (hot flushes, bone mineral density loss) and require add-back therapy for long-term use 4, 8, 6. GnRH antagonists with add-back therapy may be offered as second-line treatment as an alternative to GnRH agonists with add-back therapy 4.
Treatment Algorithm
Start with first-line therapy: Choose between oral progestins (particularly dienogest 2 mg), depot progestagens, LNG-IUS, or combined oral contraceptives based on contraceptive needs and side effect tolerance.
If first-line fails after 3-6 months: Escalate to second-line therapy with either:
- GnRH agonist + add-back therapy (at least 3 months), OR
- Oral GnRH antagonist + add-back therapy
Monitor for efficacy at 3-6 months and adjust accordingly.
For severe endometriosis: Medical treatment alone may not be sufficient, and surgical consultation should be considered 1.
Important Caveats
- No medical therapy eradicates endometriosis lesions—all treatments are suppressive, not curative 1, 6.
- Symptom recurrence is common: Up to 44% of women experience recurrence within one year after surgery 1.
- Progestins may cause: Depression, decreased libido, weight gain, breast tenderness, and lipid alterations 6.
- Long-term GnRH therapy requires bone density monitoring and add-back therapy to prevent significant bone loss 1, 8.
- Treatment choice must consider: Age, reproductive plans, pain intensity, disease severity, previous treatment response, bone health, cost, and availability 10, 8.